We are committed to finding a cure for WM.

Article – “Detection of MYD88 L265P…”

Attached please find our March 2014 published manuscript: “Detection of MYD88 L265P in peripheral blood of patients with Waldenström’s Macroglobulinemia and IgM monoclonal gammopathy of undetermined significance“.

The high prevalence of MYD88 L265P in lymphoplasmacytic cells from bone… Continue reading

Article – Gene ‘driver’ of Waldenstrom’s

 

Gene ‘driver’ of Waldenstrom’s Macroglobulinemia in up to one-third of patients identified

NEW ORLEANS— In nearly one-third of patients with Waldenstrom’s Macroglobulinemia, a specific genetic mutation switches on the disease, and a new drug that blocks the defective gene… Continue reading

Hallmarks of Cancer: The Next Generation

Excerpt:

” The hallmarks of cancer comprise six biological capabilities acquired during the multistep development of human tumors. The hallmarks constitute an organizing principle for rationalizing the complexities of neoplastic disease. They include sustaining proliferative signaling. evading growth suppressors, resisting… Continue reading

Video: Dr. Stephen Treon lecture September 2013

In the beginning of September, Dr Treon was invited to participate as a Guest Lecturer on Waldenstrom’s macroglobulinemia for participating Polish physicians and medical specialists. It was a overwhelming turnout and WM left a large impression in Eastern Europe. The… Continue reading

Ibrutinib Monotherapy Clinical Trial Data

For those who are interested in learning about the current activity with Ibrutinib, please read the article below. This is the PR news release on the presentation in Lugano on Ibrutinib activity in relapsed/refractory WM which Dr. Treon had done a few weeks ago in Lugano, Switzerland during the Lymphoma Conference.  Well over 3,000 physicians attended his lecture on this drug.

 

Ibrutinib Monotherapy Clinical Trial Data in Patients with Waldenstrom’s Macroglobulinemia Presented at the International Conference on Malignant Lymphoma in Lugano, Switzerland (via PR Newswire)

SUNNYVALE, Calif., June 20, 2013 /PRNewswire/ — Pharmacyclics, Inc. (the “Company”) (Nasdaq: PCYC) today announced results of a study evaluating ibrutinib, an investigational oral Bruton’s tyrosine kinase (BTK) inhibitor in patients with Waldenstrom…

Continue reading